Sen. Brown Vows Floor Fight On Follow-on Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
But he'll need to find a length of brand exclusivity that attracts enough senators while continuing to satisfy generic firms and their allies.
You may also be interested in...
Teva Launching "6 vs 12" Campaign On Follow-On Biologics
Six-video series will profile patients struggling to pay for biologics in effort to make the case for brand exclusivity shorter than 12 years.
Teva Launching "6 vs 12" Campaign On Follow-On Biologics
Six-video series will profile patients struggling to pay for biologics in effort to make the case for brand exclusivity shorter than 12 years.
And Then There Were 12: Follow-on Biologics Picture Coming Into Focus
It almost seems like the conference committee negotiations for follow-on biologics legislation have begun, but the two actors that the generic industry expects to best represent its issues - Rep. Henry Waxman, D-Calif., and President Obama - are not at the table